GlassScriptPhysician profile
Dara Holder
NPI 1528313822
$3,124.97
in general payments reported to CMS, 2019-2025
25 companies · $519 in 2025
The $519 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $404 · 2021: $454 · 2022: $104 · 2023: $31.45 · 2024: $1,614 · 2025: $519.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,285 · Travel and Lodging: $879.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,285.31 |
| Travel and Lodging | $878.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Procept Biorobotics Corporation | $1,229.74 | 2023-2025 | Aquabeam System, Aquabeam Robotic System |
| Astellas Pharma US INC | $347.79 | 2020-2022 | |
| Janssen Biotech, INC. | $232.65 | 2020-2022 | |
| Valencia Technologies Corporation | $207.84 | 2024 | Ecoin Device Kit |
| Calyxo, INC. | $199.34 | 2025 | Cvac Aspiration System |
| Medtronic, INC. | $143.73 | 2024-2025 | Interstim |
| Teleflex LLC | $112.65 | 2024 | Urolift |
| Srs Medical Systems, INC. | $109.56 | 2025 | Urocuff-Dc Disposable, Single, Ct3000 Pro Base Unit |
| Abbvie INC. | $95.79 | 2020-2021 | |
| Innovation Technologies INC | $85.53 | 2024 | Irrisept |
| Bayer Healthcare Pharmaceuticals INC. | $74.38 | 2020-2025 | |
| Alnylam Pharmaceuticals INC. | $44.38 | 2021 | |
| Antares Pharma, INC. | $31.48 | 2020-2021 | |
| Dendreon Pharmaceuticals LLC | $23.51 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $23.35 | 2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myovant Sciences INC. | $21.49 | 2022 | |
| Boston Scientific Corporation | $21.29 | 2021 | |
| Olympus America INC. | $17.49 | 2022 | |
| Ferring Pharmaceuticals INC. | $17.16 | 2020 | |
| Endo Pharmaceuticals INC. | $16.73 | 2020 | |
| Pfizer INC. | $15.47 | 2020 | |
| Novartis Pharmaceuticals Corporation | $14.42 | 2024 | |
| Myriad Genetic Laboratories, INC. | $13.87 | 2021 | |
| Clarus Therapeutics INC. | $12.84 | 2021 | |
| Acerus Pharmaceuticals Corporation | $12.49 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dara Holder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.